Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
BJU International|September 3, 2011
Time trends in prostate cancer surgery: data from an Internet-based multicentre databaseMartin Schostak, Daniel Baumunk, Anita Jagota, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaManfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
Lancet (London, England)|November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialMatthew R Smith, Fred Saad, Robert Coleman, et al.
Journal for Immunotherapy of Cancer|June 18, 2015
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyHubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
BJU International|September 3, 2011
Time trends in prostate cancer surgery: data from an Internet-based multicentre databaseMartin Schostak, Daniel Baumunk, Anita Jagota, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
European Urology|November 3, 2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeAxel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaManfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
Lancet (London, England)|November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialMatthew R Smith, Fred Saad, Robert Coleman, et al.
Journal for Immunotherapy of Cancer|June 18, 2015
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyHubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, et al.
Pageof 29